The genetic analysis of ovarian cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

25 citing papers in PubMed.

1. Characterization of RNF144B and PPP2R2A identified by a novel approach using TCGA data in ovarian cancer.Scientific reports · 2025
   Article
2. Complexity of the Genetic Background of Oncogenesis in Ovarian Cancer-Genetic Instability and Clinical Implications.Cells · 2024
   Review
3. The Unique Biology behind the Early Onset of Breast Cancer.Genes · 2021
   Review
4. Exploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma.PloS one · 2013
   Article
5. Genomic aberrations in borderline ovarian tumors.Journal of translational medicine · 2010
   Article
6. The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer.Journal of cancer research and clinical oncology · 2010
   Article
7. Chemotherapy drug response in ovarian cancer cells strictly depends on a cathepsin D-Bax activation loop.Journal of cellular and molecular medicine · 2009
   Article
8. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2008
   Review
9. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis.American journal of obstetrics and gynecology · 2008
   Review
10. RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer.Oncogene · 2007
    Article
11. Reduced expression of chemokine (C-C motif) ligand-2 (CCL2) in ovarian adenocarcinoma.British journal of cancer · 2005
    Article
12. Tumor formation in p53 mutant ovaries transplanted into wild-type female hosts.Oncogene · 2004
    Article
13. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.The American journal of pathology · 2004
    Review
14. Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer.British journal of cancer · 2003
    Article
15. The human homologue of unc-93 maps to chromosome 6q27 - characterisation and analysis in sporadic epithelial ovarian cancer.BMC genetics · 2002
    Article
16. Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer.Molecular pathology : MP · 2002
    Article
17. Physical and transcript map of the region between D6S264 and D6S149 on chromosome 6q27, the minimal region of allele loss in sporadic epithelial ovarian cancer.Oncogene · 2002
    Article
18. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.British journal of cancer · 2001
    Article
19. Decreased expression of the Id3 gene at 1p36.1 in ovarian adenocarcinomas.British journal of cancer · 2001
    Article
20. Frequent loss of heterozygosity at 1p36 in ovarian adenocarcinomas but the gene encoding p73 is unlikely to be the target.Oncogene · 1999
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as